CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Open Access
- 23 March 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 130 (5), 2435-2450
- https://doi.org/10.1172/JCI131133
Abstract
The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to lethal castration-resistant prostate cancer (CRPC) are poorly understood. Identification of clinically relevant genetic alterations leading to CRPC may reveal potential vulnerabilities for cancer therapy. Here we find that CUB domain-containing protein 1 (CDCP1), a transmembrane protein that acts as a substrate for SRC family kinases (SFKs), is overexpressed in a subset of CRPC. Notably, CDCP1 cooperates with the loss of the tumor suppressor gene PTEN to promote the emergence of metastatic prostate cancer. Mechanistically, we find that androgens suppress CDCP1 expression and that androgen deprivation in combination with loss of PTEN promotes the upregulation of CDCP1 and the subsequent activation of the SRC/MAPK pathway. Moreover, we demonstrate that anti-CDCP1 immunoliposomes (anti-CDCP1 ILs) loaded with chemotherapy suppress prostate cancer growth when administered in combination with enzalutamide. Thus, our study identifies CDCP1 as a powerful driver of prostate cancer progression and uncovers different potential therapeutic strategies for the treatment of metastatic prostate tumors.This publication has 59 references indexed in Scilit:
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor CellsCancer Research, 2012
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerCancer Cell, 2011
- Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancerProceedings of the National Academy of Sciences of the United States of America, 2011
- Phosphorylation of Trask by Src Kinases Inhibits Integrin Clustering and Functions in Exclusion with Focal Adhesion SignalingMolecular and Cellular Biology, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Subtle variations in Pten dose determine cancer susceptibilityNature Genetics, 2010
- A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesisJCI Insight, 2010
- Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic processBMC Cancer, 2007
- Pten Dose Dictates Cancer Progression in the ProstatePLoS Biology, 2003